Please assess the completion status of the following clinical trial:

Trial Title: Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previous participation in CHAMPS study~* Participation in a study site willing to participate in the CHAMPIONS10 extension study~* Willingness to enroll in the CHAMPIONS 10 extension~* Willingness to sign informed consent~Exclusion Criteria:~* Discovery of an alternative neurological disorder other than MS as a cause of initial neurological symptoms~* A severe systemic disease with likely mortality within 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Treatment Group (Type: EXPERIMENTAL): Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
- Delayed Treatment Group (Type: ACTIVE_COMPARATOR): Delayed initiation of of Interferon beta-1a IM once weekly at diagnosis of clinically definite MS, at conclusion of initial CHAMPS study or during long term observation

Based on this trial design, predict the completion outcome and termination type (if applicable).